Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) has been assigned a consensus recommendation of “Buy” from the fifteen analysts that are currently covering the stock, Marketbeat reports. Six equities research analysts have rated the stock with a hold rating, six have issued a buy rating and two have assigned a strong buy rating to the company. The average 1-year target price among analysts that have updated their coverage on the stock in the last year is $21.45.

A number of brokerages have issued reports on SCMP. UBS Group lowered Sucampo Pharmaceuticals from a “buy” rating to a “neutral” rating and set a $18.00 price target for the company. in a research note on Friday, January 5th. B. Riley lowered Sucampo Pharmaceuticals from a “buy” rating to a “neutral” rating and set a $18.00 price target for the company. in a research note on Tuesday, December 26th. ValuEngine upgraded Sucampo Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Sunday, December 31st. Maxim Group lowered Sucampo Pharmaceuticals to a “hold” rating in a research report on Monday, January 1st. Finally, Leerink Swann restated a “market perform” rating and set a $15.00 price objective on shares of Sucampo Pharmaceuticals in a research report on Tuesday, January 2nd.

In other news, insider Peter A. Kiener sold 50,000 shares of the firm’s stock in a transaction dated Thursday, December 7th. The stock was sold at an average price of $16.50, for a total transaction of $825,000.00. Following the completion of the transaction, the insider now owns 52,023 shares in the company, valued at $858,379.50. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Company insiders own 4.13% of the company’s stock.

Institutional investors have recently modified their holdings of the company. Swiss National Bank grew its position in shares of Sucampo Pharmaceuticals by 22.3% during the second quarter. Swiss National Bank now owns 43,859 shares of the biopharmaceutical company’s stock valued at $461,000 after purchasing an additional 8,000 shares in the last quarter. Point72 Asset Management L.P. bought a new position in shares of Sucampo Pharmaceuticals in the 3rd quarter valued at about $21,989,000. Royce & Associates LP lifted its holdings in shares of Sucampo Pharmaceuticals by 9.7% in the 3rd quarter. Royce & Associates LP now owns 1,171,731 shares of the biopharmaceutical company’s stock valued at $13,826,000 after acquiring an additional 103,808 shares during the last quarter. GSA Capital Partners LLP lifted its holdings in shares of Sucampo Pharmaceuticals by 636.4% in the 3rd quarter. GSA Capital Partners LLP now owns 112,170 shares of the biopharmaceutical company’s stock valued at $1,324,000 after acquiring an additional 96,937 shares during the last quarter. Finally, Dimensional Fund Advisors LP lifted its holdings in shares of Sucampo Pharmaceuticals by 1.0% in the 2nd quarter. Dimensional Fund Advisors LP now owns 1,570,172 shares of the biopharmaceutical company’s stock valued at $16,487,000 after acquiring an additional 15,528 shares during the last quarter. Hedge funds and other institutional investors own 64.55% of the company’s stock.

Shares of Sucampo Pharmaceuticals (NASDAQ:SCMP) opened at $17.95 on Friday. Sucampo Pharmaceuticals has a 12 month low of $9.30 and a 12 month high of $18.75. The company has a quick ratio of 4.46, a current ratio of 5.11 and a debt-to-equity ratio of 7.37. The stock has a market capitalization of $849.02, a price-to-earnings ratio of -5.46, a price-to-earnings-growth ratio of 5.06 and a beta of 1.45.

Sucampo Pharmaceuticals (NASDAQ:SCMP) last issued its quarterly earnings results on Wednesday, November 1st. The biopharmaceutical company reported $0.27 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.25 by $0.02. Sucampo Pharmaceuticals had a positive return on equity of 74.58% and a negative net margin of 60.24%. The business had revenue of $61.27 million during the quarter, compared to analyst estimates of $58.05 million. During the same quarter in the prior year, the business posted $0.30 EPS. Sucampo Pharmaceuticals’s revenue for the quarter was up 5.9% compared to the same quarter last year. equities analysts expect that Sucampo Pharmaceuticals will post 1.12 earnings per share for the current fiscal year.

WARNING: This news story was first reported by TheOlympiaReport and is the property of of TheOlympiaReport. If you are reading this news story on another site, it was illegally copied and reposted in violation of US and international trademark & copyright laws. The correct version of this news story can be viewed at https://theolympiareport.com/2018/01/20/sucampo-pharmaceuticals-inc-scmp-receives-average-rating-of-buy-from-analysts.html.

Sucampo Pharmaceuticals Company Profile

Sucampo Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products. Its primary focus areas are gastroenterology, ophthalmology and oncology-related disorders. Its product candidates include VTS-270, Lubiprostone (AMITIZA), Unoprostone is opropyl (RESCULA) and CPP-1X/sulindac combination product.

Analyst Recommendations for Sucampo Pharmaceuticals (NASDAQ:SCMP)

Receive News & Ratings for Sucampo Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sucampo Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.